TCM
HAE icon

Tamarack Capital Management’s Haemonetics HAE Stock Holding History

Tamarack Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-225,000
Closed -$9.3M – 33
2013
Q2 		$9.3M Buy
+225,000
New +$9.11M 5.21% 6

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tamarack Capital Management's HAE Position: Q3 2013 in Review

Tamarack Capital Management sold out of Haemonetics (HAE) in Q3 2013, closing a stake of 225,000 shares — an estimated $9.3M sold.

Tamarack Capital Management first reported a position in HAE in Q2 2013 and held it in 1 quarter. The position peaked at $9.3M in Q2 2013. 192 funds tracked by Wall St. Rank hold HAE as of Q3 2013.

  • Tamarack Capital Management reported no remaining Haemonetics position as of Q3 2013 after selling out during the quarter.
  • Tamarack Capital Management sold 225,000 Haemonetics shares in Q3 2013, an estimated $9.3M.
  • Tamarack Capital Management first reported a position in Haemonetics in Q2 2013 and held it in 1 quarter.
  • Tamarack Capital Management's Haemonetics position peaked at $9.3M in Q2 2013.
  • 192 funds tracked by Wall St. Rank held Haemonetics as of Q3 2013.

Based on Tamarack Capital Management's 13F filing for Q3 2013, filed 7 Nov 2013.